Paris: AstraZeneca Plc said its blood-cancer medicine Calquence failed to help patients hospitalized with respiratory symptoms of Covid-19.
The group of patients taking the drug in addition to standard care didn’t show fewer deaths or respiratory failures, the U.K. drugmaker said in a statement. Details of the intermediate clinical trials will be presented in due course, the company said.
The Astra study is one of many programs to evaluate known treatments — from antiviral drugs to plasma from recovered patients — against the pandemic virus. Other disappointments include Sanofi’s rheumatoid arthritis medicine Kevzara.
Astra also has a Covid vaccine candidate under development with the University of Oxford, as well as a potential antibody treatment for the disease.- Bloomberg
Also read: After Pfizer, now Moderna will be in the spotlight for its Covid vaccine data